Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Novel high-risk acute myeloid leukemia subgroup with ERG amplification and Biallelic loss of TP53.
Percutaneous treatment of focal vs. diffuse in-stent restenosis: a prospective randomized comparison of conventional therapies.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Novel high-risk acute myeloid leukemia subgroup with ERG amplification and Biallelic loss of TP53.
Novel high-risk acute myeloid leukemia subgroup with ERG amplification and Biallelic loss of TP53. Cancer Genet. 2023 04; 272-273:23-28.
View in:
PubMed
subject areas
Humans
In Situ Hybridization, Fluorescence
Leukemia, Myeloid, Acute
Loss of Heterozygosity
Mutation
Prognosis
Transcriptional Regulator ERG
Tumor Suppressor Protein p53
authors with profiles
Cynthia A. Schandl
Daynna J. Wolff
Dongjun Chung
Brian Timothy Hess